Takeda Pharmaceutical is scheduled to report its second-quarter results on Thursday. Let’s take a closer look at what we can expect from the pharmaceutical giant:
Net Profit Forecast
Analysts predict that Takeda will see a net profit increase of 14% to 70.41 billion yen ($470.3 million) for the three-month period ending on September 30. This compares to a net profit of Y61.7 billion recorded during the same period last year.
According to a poll conducted by Quick, second-quarter revenue is estimated to have dropped by 2.8% to Y973.875 billion.
During the first quarter, Takeda experienced notable revenue growth in several key products. Sales of the ulcerative colitis drug, Entyvio, increased by 14% to Y192.0 billion, while sales of Vyvanse, a drug used to treat attention deficit hyperactivity disorder, saw a 23% increase to Y123.2 billion. Investors are particularly interested in monitoring the sales performance of these key drugs, especially considering Takeda’s loss of U.S. market exclusivity for Vyvanse in late August.
Takeda’s net debt-to-adjusted Ebitda ratio rose to 2.9 at the end of June from 2.6 at the end of March. Investors are closely watching for any changes in the company’s leverage.
Takeda has already projected a 4.7% drop in revenue to Y3.840 trillion for the fiscal year ending in March 2024, with net profit expected to fall by 55% to Y142.00 billion. Investors are paying close attention to any potential adjustments that may be made to Takeda’s annual guidance.